BCL2 and acute myeloid leukemia: In the present study, we observed an equal distribution of NPM1 and IDH2 mutations between BCL-2− and BCL-2+ AML patients, suggesting that BCL-2 positivity is not a prerequisite for obtaining a response to venetoclax therapy.